PMID- 30608388
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 1
DP  - 2019 Jan
TI  - A meta-analysis of efficacy and safety of sorafenib versus other targeted agents 
      for metastatic renal cell carcinoma.
PG  - e13779
LID - 10.1097/MD.0000000000013779 [doi]
LID - e13779
AB  - BACKGROUND: Molecular targeted therapies were found to be efficacious and safer 
      in the treatment of metastatic renal cell carcinoma (mRCC). Sorafenib is the 
      first target agent (TA) to report a benefit in this disease and has largely 
      established a prominent role in progression-free survival (PFS). However, there 
      have been conflicting results across the trials that evaluated the efficacy of 
      sorafenib. OBJECTIVE: The aim of the study was to perform a meta-analysis to 
      compare the efficacy and safety of sorafenib in first-line treatments of mRCC. 
      METHODS: We searched online electronic databases: PubMed, Embase, and the 
      Cochrane Library updated on September 2017. Trials on the efficacy of sorafenib 
      in first-line treatments of advanced RCC were included, of which the primary 
      outcomes were objective response rate (ORR), PFS, overall survival (OS), and 
      grade 3/4 adverse events (AEs). RESULTS: A total of 5 trials were included in 
      this analysis. The group of AEs showed significantly improved PFS (odds ratio 
      [OR] = 0.78, 95% confidence interval [CI] = 0.70-0.86, P < .001), as well with 
      the ORR (OR = 1.89, 95%CI = 1.38-2.59, P < .0001) compared with sorafenib. 
      However, there was no significant difference in OS (OR = 0.97, 95%CI = 0.78-1.22, 
      P = .82). CONCLUSION: Sorafenib did not achieve efficacy and safety benefit in 
      patients with mRCC compared with those treated with TAs. The role of sorafenib in 
      first-line treatments of mRCC may change in favor of newer drugs. More research 
      is needed to confirm whether these new TAs could replace sorafenib as the gold 
      standard in the future.
FAU - Wang, Hai-Tao
AU  - Wang HT
AD  - Department of Urology, Beijing Shijitan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Xia, Ming
AU  - Xia M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Molecular Targeted Therapy/methods/*statistics & numerical data
MH  - Odds Ratio
MH  - Progression-Free Survival
MH  - Randomized Controlled Trials as Topic
MH  - Sorafenib/*therapeutic use
MH  - Treatment Outcome
PMC - PMC6344165
COIS- The authors have no funding and conflicts of interest to disclose.
EDAT- 2019/01/05 06:00
MHDA- 2019/01/12 06:00
PMCR- 2019/01/04
CRDT- 2019/01/05 06:00
PHST- 2019/01/05 06:00 [entrez]
PHST- 2019/01/05 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
PHST- 2019/01/04 00:00 [pmc-release]
AID - 00005792-201901040-00008 [pii]
AID - MD-D-18-02078 [pii]
AID - 10.1097/MD.0000000000013779 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Jan;98(1):e13779. doi: 10.1097/MD.0000000000013779.